The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors - PubMed (original) (raw)

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

R B Kim et al. J Clin Invest. 1998.

Abstract

Currently available HIV-1 protease inhibitors are potent agents in the therapy of HIV-1 infection. However, limited oral absorption and variable tissue distribution, both of which are largely unexplained, complicate their use. We tested the hypothesis that P-glycoprotein is an important transporter for these agents. We studied the vectorial transport characteristics of indinavir, nelfinavir, and saquinavir in vitro using the model P-glycoprotein expressing cell lines L-MDR1 and Caco-2 cells, and in vivo after intravenous and oral administration of these agents to mice with a disrupted mdr1a gene. All three compounds were found to be transported by P-glycoprotein in vitro. After oral administration, plasma concentrations were elevated 2-5-fold in mdr1a (-/-) mice and with intravenous administration, brain concentrations were elevated 7-36-fold. These data demonstrate that P-glycoprotein limits the oral bioavailability and penetration of these agents into the brain. This raises the possibility that higher HIV-1 protease inhibitor concentrations may be obtained by targeted pharmacologic inhibition of P-glycoprotein transport activity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):2031-5 - PubMed
    1. Annu Rev Biochem. 1993;62:385-427 - PubMed
    1. J Neuropathol Exp Neurol. 1994 May;53(3):284-94 - PubMed
    1. Cell. 1994 May 20;77(4):491-502 - PubMed
    1. J Infect Dis. 1994 Dec;170(6):1361-6 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources